.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,112,565

« Back to Dashboard

Details for Patent: 7,112,565

Title:Stabilized pharmaceutical composition in lyophilized form
Abstract: A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): ##STR00001## wherein R.sup.1 is a hydrogen atom or an acyl group and R.sup.2 and R.sup.3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
Inventor(s): Sawai; Seiji (Takarazuka, JP), Kasai; Akihiro (Ikoma, JP), Ohtomo; Kazumi (Ibaraki, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Filing Date:Feb 06, 2004
Application Number:10/772,281
Claims:1. A stabilized pharmaceutical composition in lyophilized form which comprises a cyclic polypeptide compound of the general formula (I): ##STR00006## wherein R.sup.1 is a hydrogen atom or an acyl group and R.sup.2 and R.sup.3 are, the same or different, a hydrogen atom or a hydroxyl group; or its pharmaceutically acceptable salt; and one or more compound(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride.

2. The composition according to claim 1 in which R.sup.1 is represented by the formula: ##STR00007## and R.sup.2 and R.sup.3 are hydroxy groups.

3. The composition according to claim 1, wherein said compound is a disaccharide.

4. The composition according to claim 1, wherein said compound is maltose or sucrose.

5. The composition according to claim 1, wherein said compound is lactose.

6. The composition according to claim 1, which contains 0.4 to 50 parts by weight of said compound(s) with respect to one part by weight of the cyclic polypeptide compound or its pharmaceutically acceptable salt.

7. The composition according to claim 1, which contains 0.1 to 400 mg of the cyclic polypeptide compound or its pharmaceutically acceptable salt in a single unit dose.

8. The composition according to claim 1 prepared by: dissolving the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt, the said compound(s), and optionally a pH adjustor, in a purified water and lyophilizing the solution.

9. The composition of claim 1 which when dissolved in purified water, gives a solution of pH 4.0 to 7.5.

10. The composition of claim 1 which contains 3.4% or less by weight of water.

11. A method for preparing a stabilized pharmaceutical composition comprising: dissolving a cyclic polypeptide compound of the general formula (I): ##STR00008## wherein R.sup.1 is a hydrogen atom or an acyl group and R.sup.2 and R.sup.3 are, the same or different, a hydrogen atom or a hydroxyl group, or its pharmaceutically acceptable salt and one or more compounds selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride in water, and optional a pH adjustor, and lyophilizing the solution.

12. An injection preparation prepared by dissolving the composition of claim 1 in isotonic sodium chloride solution.

13. A commercial package comprising: the pharmaceutical composition of claim 1 and written instructions for use thereof.

14. The composition of claim 1, wherein said compound is a polysaccharide.

15. The composition of claim 1, wherein said compound is sodium chloride.

16. The composition of claim 1, further comprising a pH adjustor.

17. The composition of claim 16, wherein the pH adjustor is acidic.

18. The composition of claim 16, wherein the pH adjustor is basic.

19. An aqueous composition comprising the composition of claim 1 and water.

20. The aqueous composition of claim 19, wherein the water is present in an isotonic sodium chloride solution.

21. The aqueous composition of claim 19, wherein the water consists essentially of purified water.

22. A method for treating a fungal disease comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

23. The method of claim 22, wherein said disease is selected from the group consisting of dermatophytosis, pityriasis versicolor, candidiasis, cryptococcosis, geotrichosis, trichosporosis, aspergillosis, penicilliosis, fusariosis, zygomycosis, sporortrichosis, chromomycosis, coccidioidomycosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, pseudallescheriosis, mycetoma, mycotic keratitis, otomycosis and pneumocystosis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc